References
- GOLD Executive Summary (revised 2014)Global strategy for the diagnosis, management and prevention of COPD Available from: http://www.goldcopd.com/Accessed November 5, 2014
- BednarekMMaciejewskiJWozniakMKucaPZielinskiJPrevalence, severity and underdiagnosis of COPD in the primary care settingThorax200863540240718234906
- Rocznik demograficzny 2010 [Statistical Yearbook 2010]Warsaw, PolandGłówny Urząd Statystyczny2011 Polish
- GóreckaDJassemEPierzchałaWŚliwińskiPZalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP) [Recommendations of the Polish Society of Lung Diseases for diagnosis and treatment of chronic obstructive pulmonary disease (COPD)]Pneumonol Alergol Pol2012803220254 Polish22562274
- CramerJABradley-KennedyCScaleraATreatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J2007141252917315055
- BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
- TashkinDPCelliBSennSfor UPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
- DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
- TonnelABPerezTGrosboisJMEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPDInt J Chron Obstruct Pulmon Dis20083230131018686739
- DecramerMCelliBKestenSLystigTMehraSTashkinDPfor UPLIFT InvestigatorsEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a pre-specified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
- TroostersTCelliBLystigTfor UPLIFT InvestigatorsTiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trialEur Respir J2010361657320185426
- VogelmeierCHedererBGlaabTfor POET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
- MathioudakisAGKanavidisPChatzimavridou-GrigoriadouVTiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysisJ Aerosol Med Pulm Drug Deliv2014271435023521168
- KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD01084424671923
- Spirivia Respimat 25 microgram, solution for inhalation [summary of product characteristics] IngelheimGermanyBoehringer Ingelheim2014
- DoddJWHoggLNolanJThe COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective studyThorax201166542542921398686
- JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
- CATestonline.org. COPD Assessment TestImproving COPD communication, improving care Available from: http://www.CATestonline.org/Accessed November 5, 2014
- KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
- FležarMJahnz-RóżykKEnacheGSOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern EuropeInt J Chron Obstruct Pulmon Dis2013848349224159258